Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia

J. Takada, H. Ooboshi, T. Ago, T. Kitazono, H. Yao, K. Kadomatsu, T. Muramatsu, S. Ibayashi, M. Iida

研究成果: ジャーナルへの寄稿記事

33 引用 (Scopus)

抄録

Gene therapy may be a promising approach for treatment of brain ischemia. In this study, we examined the effect of postischemic gene transfer of midkine, a heparin-binding neurotrophic factor, using a focal brain ischemia model with the photothrombotic occlusion method. At 90 min after induction of brain ischemia in spontaneously hypertensive rats, a replication-deficient recombinant adenovirus encoding mouse midkine (AdMK, n = 7) or a control vector encoding β-galactosidase (Adβgal, n = 7) was injected into the lateral ventricle ipsilateral to ischemia. At 2 days after ischemia, we determined infarct volume by 2,3,5-triphenyltetrazolium chloride staining. There were no significant differences in cerebral blood flow 1 h after ischemia between AdMK and Adβgal groups. Infarct volume of AdMK group was 51±27 mm3, which was significantly smaller than that of Adβgal group (86±27 mm3, P < 0.05). TUNEL-positive and cleaved caspase-3-positive cells in the periischemic area of AdMK-treated rats were significantly fewer than those in Adβgal-treated rats, suggesting that the reduction of infarct volume by midkine was partly mediated by its antiapoptotic action. Thus, gene transfer of midkine to the ischemic brain may be effective in the treatment of brain ischemia.

元の言語英語
ページ(範囲)487-493
ページ数7
ジャーナルGene Therapy
12
発行部数6
DOI
出版物ステータス出版済み - 3 1 2005

Fingerprint

Nerve Growth Factors
Brain Ischemia
Ischemia
Genes
Cerebrovascular Circulation
Galactosidases
Lateral Ventricles
In Situ Nick-End Labeling
Inbred SHR Rats
Adenoviridae
Caspase 3
Genetic Therapy
Staining and Labeling
midkine
Brain
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

これを引用

Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia. / Takada, J.; Ooboshi, H.; Ago, T.; Kitazono, T.; Yao, H.; Kadomatsu, K.; Muramatsu, T.; Ibayashi, S.; Iida, M.

:: Gene Therapy, 巻 12, 番号 6, 01.03.2005, p. 487-493.

研究成果: ジャーナルへの寄稿記事

Takada, J, Ooboshi, H, Ago, T, Kitazono, T, Yao, H, Kadomatsu, K, Muramatsu, T, Ibayashi, S & Iida, M 2005, 'Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia', Gene Therapy, 巻. 12, 番号 6, pp. 487-493. https://doi.org/10.1038/sj.gt.3302434
Takada, J. ; Ooboshi, H. ; Ago, T. ; Kitazono, T. ; Yao, H. ; Kadomatsu, K. ; Muramatsu, T. ; Ibayashi, S. ; Iida, M. / Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia. :: Gene Therapy. 2005 ; 巻 12, 番号 6. pp. 487-493.
@article{2e771f2f48304369897b62347e679d27,
title = "Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia",
abstract = "Gene therapy may be a promising approach for treatment of brain ischemia. In this study, we examined the effect of postischemic gene transfer of midkine, a heparin-binding neurotrophic factor, using a focal brain ischemia model with the photothrombotic occlusion method. At 90 min after induction of brain ischemia in spontaneously hypertensive rats, a replication-deficient recombinant adenovirus encoding mouse midkine (AdMK, n = 7) or a control vector encoding β-galactosidase (Adβgal, n = 7) was injected into the lateral ventricle ipsilateral to ischemia. At 2 days after ischemia, we determined infarct volume by 2,3,5-triphenyltetrazolium chloride staining. There were no significant differences in cerebral blood flow 1 h after ischemia between AdMK and Adβgal groups. Infarct volume of AdMK group was 51±27 mm3, which was significantly smaller than that of Adβgal group (86±27 mm3, P < 0.05). TUNEL-positive and cleaved caspase-3-positive cells in the periischemic area of AdMK-treated rats were significantly fewer than those in Adβgal-treated rats, suggesting that the reduction of infarct volume by midkine was partly mediated by its antiapoptotic action. Thus, gene transfer of midkine to the ischemic brain may be effective in the treatment of brain ischemia.",
author = "J. Takada and H. Ooboshi and T. Ago and T. Kitazono and H. Yao and K. Kadomatsu and T. Muramatsu and S. Ibayashi and M. Iida",
year = "2005",
month = "3",
day = "1",
doi = "10.1038/sj.gt.3302434",
language = "English",
volume = "12",
pages = "487--493",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia

AU - Takada, J.

AU - Ooboshi, H.

AU - Ago, T.

AU - Kitazono, T.

AU - Yao, H.

AU - Kadomatsu, K.

AU - Muramatsu, T.

AU - Ibayashi, S.

AU - Iida, M.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Gene therapy may be a promising approach for treatment of brain ischemia. In this study, we examined the effect of postischemic gene transfer of midkine, a heparin-binding neurotrophic factor, using a focal brain ischemia model with the photothrombotic occlusion method. At 90 min after induction of brain ischemia in spontaneously hypertensive rats, a replication-deficient recombinant adenovirus encoding mouse midkine (AdMK, n = 7) or a control vector encoding β-galactosidase (Adβgal, n = 7) was injected into the lateral ventricle ipsilateral to ischemia. At 2 days after ischemia, we determined infarct volume by 2,3,5-triphenyltetrazolium chloride staining. There were no significant differences in cerebral blood flow 1 h after ischemia between AdMK and Adβgal groups. Infarct volume of AdMK group was 51±27 mm3, which was significantly smaller than that of Adβgal group (86±27 mm3, P < 0.05). TUNEL-positive and cleaved caspase-3-positive cells in the periischemic area of AdMK-treated rats were significantly fewer than those in Adβgal-treated rats, suggesting that the reduction of infarct volume by midkine was partly mediated by its antiapoptotic action. Thus, gene transfer of midkine to the ischemic brain may be effective in the treatment of brain ischemia.

AB - Gene therapy may be a promising approach for treatment of brain ischemia. In this study, we examined the effect of postischemic gene transfer of midkine, a heparin-binding neurotrophic factor, using a focal brain ischemia model with the photothrombotic occlusion method. At 90 min after induction of brain ischemia in spontaneously hypertensive rats, a replication-deficient recombinant adenovirus encoding mouse midkine (AdMK, n = 7) or a control vector encoding β-galactosidase (Adβgal, n = 7) was injected into the lateral ventricle ipsilateral to ischemia. At 2 days after ischemia, we determined infarct volume by 2,3,5-triphenyltetrazolium chloride staining. There were no significant differences in cerebral blood flow 1 h after ischemia between AdMK and Adβgal groups. Infarct volume of AdMK group was 51±27 mm3, which was significantly smaller than that of Adβgal group (86±27 mm3, P < 0.05). TUNEL-positive and cleaved caspase-3-positive cells in the periischemic area of AdMK-treated rats were significantly fewer than those in Adβgal-treated rats, suggesting that the reduction of infarct volume by midkine was partly mediated by its antiapoptotic action. Thus, gene transfer of midkine to the ischemic brain may be effective in the treatment of brain ischemia.

UR - http://www.scopus.com/inward/record.url?scp=15944367385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944367385&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302434

DO - 10.1038/sj.gt.3302434

M3 - Article

C2 - 15703767

AN - SCOPUS:15944367385

VL - 12

SP - 487

EP - 493

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 6

ER -